Luis Raez, MD
Hematology & Oncology · Pembroke Pines, FLNPI 1922030071
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $82,038 of the $115,892 with a category attached, or 70.8%. It is spread thinly across 43 manufacturers, the largest accounting for just 13.1%. Among hematology & oncology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 252 payments — averaging $459.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$15K
- Bayer$14K
- E.r. Squibb & Sons, L.L.C.$10K
- Janssen Scientific Affairs, LLC$8K
- Novartis$7K
- AbbVie$7K
- plus $54K from 37 others
Across 132 payments — averaging $12,061 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$780K
- Eli Lilly$359K
- E.r. Squibb & Sons, L.L.C.$215K
- Partner Therapeutics, Inc.$101K
- Amgen$37K
- AbbVie$26K
- plus $75K from 6 others
What the payments were for
- Consulting fees$82,03871%
- Speaking & faculty fees$17,89015%
- Travel & lodging$7571%
- Food & beverage$13,46412%
- Education$2440%
- Charitable contribution$1,5001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vitrakvi$13,486
- RYBREVANT$11,002
- LORBRENA$5,212
- ALUNBRIG$2,970
- IMFINZI$2,629
- ANKTIVA$2,500
- TAGRISSO$2,474
- IBTROZI$2,100
- Enhertu$1,640
- IMDELLTRA (AMG 757)$1,544
- OPTUNE LUA (NOVOTTF-200T)$1,487
- DATROWAY$1,290
- EMRELIS$1,088
- Trodelvy$595
- Udenyca$523
- Cabometyx$347
- ZEPZELCA$344
- FOUNDATIONONE$318
- FOUNDATIONONE HEME$318
- FOUNDATIONONE CDX$318
How this compares
$115,892 in reported general payments places this provider in the 90th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 105 | $1,691,989 |
| TepmetkoTepotinib Hcl | 14 | $349,786 |
| GilotrifAfatinib Dimaleate | 27 | $299,162 |
| XalkoriCrizotinib | 13 | $276,882 |
| EliquisApixaban | 13 | $11,652 |
| XareltoRivaroxaban | 16 | $9,117 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 51 | $804 |
| Ondansetron OdtOndansetron | 21 | $216 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 13 | $151 |
| Folic Acid | 15 | $65 |
| Azithromycin | 17 | $61 |
| Prednisone | 11 | $59 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $15,198 | $1,691,989105 claims |
| EMD Serono, Inc.Tepmetko | $6,334 | $349,78614 claims |
| Boehringer IngelheimGilotrif | $2,438 | $299,16227 claims |
| PfizerXalkori, Eliquis | $5,627 | $288,53426 claims |
| Johnson & JohnsonXarelto | $5,806 | $9,11716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Pembroke Pines
- Jose Sandoval-SusPembroke Pines$131K
- Martin DietrichRockledge$6.2M
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Edgardo SantosFort Lauderdale$2M
- Daniel LandauOrlando$1.8M
- Wassim McHaylehAltamonte Springs$1.5M
- Edith PerezJacksonville$1.1M
- Steven FeinMiami$1M
- Vamsidhar VelchetiJacksonville$966K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.